Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR etc. |
| Sample | cell lines (A2780, DOV13, PA-1 etc.) |
| Expression Pattern | up-regulated |
| Function Description | These results suggest that MYC and PVT1 contribute independently to ovarian and breast pathogenesis when overexpressed because of genomic abnormalities. They also suggest that PVT1-mediated inhibition of apoptosis may explain why amplification of 8q24 is associated with reduced survival duration in patients treated with agents that act through apoptotic mechanisms. |
| Pubmed ID | 17908964 |
| Year | 2007 |
| Title | Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |